AURO-MONTELUKAST CHEWABLE TABLET TABLET (CHEWABLE)

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

MONTELUKAST (MONTELUKAST SODIUM)

Inapatikana kutoka:

AURO PHARMA INC

ATC kanuni:

R03DC03

INN (Jina la Kimataifa):

MONTELUKAST

Kipimo:

4MG

Dawa fomu:

TABLET (CHEWABLE)

Tungo:

MONTELUKAST (MONTELUKAST SODIUM) 4MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

10/30

Dawa ya aina:

Prescription

Eneo la matibabu:

LEUKOTRIENE MODIFIERS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0133823003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2014-03-25

Tabia za bidhaa

_ _
_ _
_Page 1 of 34 _
PRODUCT MONOGRAPH
PR
AURO-MONTELUKAST CHEWABLE TABLET
montelukast (as montelukast sodium)
4 mg and 5 mg chewable tablets
Leukotriene Receptor Antagonist
AURO PHARMA INC. Date of Revision:
3700 Steeles Avenue West, Suite # 402 November 10, 2020
Woodbridge, Ontario, L4L 8K8
CANADA
SUBMISSION CONTROL NO.: 244280
_ _
_ _
_Page 2 of 34 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
10
DOSAGE AND
ADMINISTRATION.............................................................................
11
OVERDOSAGE................................................................................................................
13
ACTION AND CLINICAL
PHARMACOLOGY............................................................
13
STORAGE AND
STABILITY.........................................................................................
17
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 17
PART II: SCIENTIFIC
INFORMATION..........................................................................
18
PHARMACEUTICAL INFORMATION
.........................................................................
18
CLINICAL TRIALS
.........................................................................................................
18
TOXICOLOGY.....................